After excluding them, we found that concurrent radiotherapy plus EGFR TKIs could also significantly prolong the CNS‐TTP (HR = 0.55, 95% CI: 0.28–0.82; P = 0.000) and OS (HR = 0.63, 95% CI: 0.45–0.81; P = 0.000) of NSCLC patients with BM (Fig. S1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.